Search

Corvus Pharmaceuticals Inc

Open

14.64 2.88

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

14.07

Max

14.4

Belangrijke statistieken

By Trading Economics

Inkomsten

-4.3M

-18M

EPS

-0.19

Werknemers

37

EBITDA

-5.3M

-17M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+107.75% upside

Dividenden

By Acuity

Volgende Winsten

3 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

57M

1.2B

Vorige openingsprijs

11.76

Vorige sluitingsprijs

14.64

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 sep 2026, 23:56 UTC

Fidelity National Financial shares are higher in after-market trading, recovering from earlier losses but remain below the 20-day moving average.

2 sep 2026, 23:56 UTC

MGM Resorts International shares are higher in after-market trading, supported by a broader market response to weaker ADP private payrolls data.

2 sep 2026, 23:56 UTC

News

Entergy Corp settled its 2025 forward sale agreements, delivering over 11 million shares for $913 million. Shares are higher in after-market trading.

2 sep 2026, 23:56 UTC

Correlated Moves

Equinix Inc. shares are higher in after-market trading, supported by a weaker ADP payrolls report indicating lower job growth than expected.

2 sep 2026, 23:56 UTC

Biogen Inc shares are higher in after-market trading, despite no specific news. Broader market dynamics may be influenced by weaker ADP payrolls data.

2 sep 2026, 23:56 UTC

Exelixis Inc shares are higher in after-market trading, though no specific news was identified. The broader market reacted to weaker ADP payroll data.

2 sep 2026, 23:56 UTC

APA Corp. shares are trading roughly flat in after-market hours. Market sentiment is influenced by weaker ADP payroll data, easing rate hike concerns.

2 sep 2026, 23:56 UTC

Abbott Laboratories shares are lower in after-market hours, reflecting a decline since Wednesday's close amid weaker-than-expected job growth reported by ADP.

2 sep 2026, 23:56 UTC

Union Pacific Corp shares are lower in after-market hours amid volatility, following disappointing ADP payroll data that may affect Federal Reserve interest rate expectations.

2 sep 2026, 23:56 UTC

T Rowe Price Group Inc shares are trading lower in after-market hours following a volatile session amid reactions to weaker-than-expected ADP payroll data.

2 sep 2026, 23:52 UTC

Mexico's inflation rate expected to stabilize around 3% amid cautious market sentiment and external risks ahead of September release.

2 sep 2026, 23:52 UTC

Mexican Inflation Data Release on September 9, Amid Cautious Optimism and Ongoing Economic Risks.

2 sep 2026, 23:52 UTC

Australia's Westpac Consumer Confidence Index set for release on September 8, 2026, amid mixed sentiments and rising economic pressures.

2 sep 2026, 23:52 UTC

US ISM Services PMI Expected to Rise Slightly to 54.3, Indicating Continued Expansion Amid Economic Challenges

2 sep 2026, 23:52 UTC

Australia's Westpac Consumer Confidence Index set for release amid cautious optimism and external inflation risks on September 8, 2026.

2 sep 2026, 23:51 UTC

Dorian LPG Ltd shares are lower in after-market hours, following five consecutive sessions of gains. The decline coincides with a weaker ADP payrolls report.

2 sep 2026, 23:51 UTC

Hackett Group Inc shares are lower in after-market hours, continuing a decline since Wednesday's close and trading below their 20-day moving average.

2 sep 2026, 23:51 UTC

Champion Homes Inc is rising in after-market trading, supported by gains in the Homebuilding sub-sector. The asset has recovered from earlier session lows.

2 sep 2026, 23:51 UTC

Essential Properties Realty Trust shares are higher in after-market trading. Broader market trends and recent economic data may be influencing this movement.

2 sep 2026, 23:51 UTC

ETF Constituents
Macro News

State Street Financial Select Sector SPDR ETF rises in after-market hours as weaker job growth eases Fed rate hike concerns and key holdings perform well.

2 sep 2026, 23:51 UTC

IQVIA Holdings Inc shares rose in after-market trading, continuing upward momentum amid a broader macroeconomic backdrop following the ADP payrolls report.

2 sep 2026, 23:51 UTC

Correlated Moves

Republic Bancorp Inc shares declined in after-hours trading, reflecting broader financial sector weakness amid disappointing job creation data from the ADP report.

2 sep 2026, 23:51 UTC

South Plains Financial Inc is trading lower in after-market hours, continuing a trend seen during the regular session amid broader market weakness following a disappointing ADP report.

2 sep 2026, 23:51 UTC

Keysight Technologies Inc shares are lower in after-market hours, continuing a decline from earlier in the session amid a challenging trading environment.

2 sep 2026, 23:51 UTC

Sylvamo Corp shares are lower in after-market trading, continuing a decline from earlier in the session amid broader market weakness following the ADP payrolls report.

2 sep 2026, 23:51 UTC

Maximus Inc shares are higher in after-market trading, rebounding from earlier lows. Weaker ADP payroll data may ease concerns over aggressive Fed rate hikes.

2 sep 2026, 23:51 UTC

New York Times Co shares are higher in after-market trading, supported by a solid market backdrop and recent ADP payrolls report indicating slower job growth.

2 sep 2026, 23:51 UTC

Best Buy Co Inc shares are higher in after-market trading, supported by gains in the Computer & Electronics Retail sub-sector and maintaining a notable high.

2 sep 2026, 23:51 UTC

U.S. equity indices rebound amid weak job growth and rising oil prices, while geopolitical tensions and climbing bond yields raise inflation concerns.

2 sep 2026, 23:51 UTC

Asian equity markets decline amid U.S.-Iran tensions and rising bond yields, while U.S. stocks rebound ahead of key jobs data impacting Fed rate outlook.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

107.75% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.5 USD  107.75%

Hoogste 33 USD

Laagste 27 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat